Literature DB >> 20200281

SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells.

Robert Brooks1, Gwenny M Fuhler, Sonia Iyer, Michelle J Smith, Mi-Young Park, Kim H T Paraiso, Robert W Engelman, William G Kerr.   

Abstract

Genetic studies revealed that SHIP1 limits blood cell production and immune regulatory cell numbers in vivo. We postulated that molecular targeting of SHIP1 might enhance blood cell production and increase immunoregulatory capacity. In this study, we report the identification of a chemical inhibitor of SHIP1, 3 alpha-aminocholestane (3AC). Treatment with 3AC significantly expands the myeloid immunoregulatory cell compartment and impairs the ability of peripheral lymphoid tissues to prime allogeneic T cell responses. In addition, 3AC treatment profoundly increases granulocyte production without triggering the myeloid-associated lung consolidation observed in SHIP1(-/-) mice. Moreover, 3AC also enhances RBC, neutrophil, and platelet recovery in myelosuppressed hosts. Intriguingly, we also find that chemical inhibition of SHIP1 triggers apoptosis of blood cancer cells. Thus, SHIP1 inhibitors represent a novel class of small molecules that have the potential to enhance allogeneic transplantation, boost blood cell production, and improve the treatment of hematologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200281      PMCID: PMC4123216          DOI: 10.4049/jimmunol.0902844

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

Review 1.  The allograft response.

Authors:  K J Lafferty; S J Prowse; S Babcock; R Gill
Journal:  Surg Clin North Am       Date:  1986-12       Impact factor: 2.741

2.  PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.

Authors:  S K Jain; M Susa; M L Keeler; N Carlesso; B Druker; L Varticovski
Journal:  Blood       Date:  1996-09-01       Impact factor: 22.113

3.  Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein.

Authors:  Z Tu; J M Ninos; Z Ma; J W Wang; M P Lemos; C Desponts; T Ghansah; J M Howson; W G Kerr
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

4.  Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation.

Authors:  Jia-Wang Wang; Julie M Howson; Tomar Ghansah; Caroline Desponts; John M Ninos; Sarah L May; Kim H T Nguyen; Noriko Toyama-Sorimachi; William G Kerr
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

5.  SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts.

Authors:  Sunao Takeshita; Noriyuki Namba; Jenny J Zhao; Yebin Jiang; Harry K Genant; Matthew J Silva; Michael D Brodt; Cheryl D Helgason; Janet Kalesnikoff; Michael J Rauh; R Keith Humphries; Gerald Krystal; Steven L Teitelbaum; F Patrick Ross
Journal:  Nat Med       Date:  2002-08-05       Impact factor: 53.440

Review 6.  Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy.

Authors:  Salvatore Siena; Simona Secondino; Laura Giannetta; Ornella Carminati; Paolo Pedrazzoli
Journal:  Crit Rev Oncol Hematol       Date:  2003-10-15       Impact factor: 6.312

7.  Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity.

Authors:  Beth E Drees; Amber Weipert; Heather Hudson; Colin G Ferguson; Leena Chakravarty; Glenn D Prestwich
Journal:  Comb Chem High Throughput Screen       Date:  2003-06       Impact factor: 1.339

Review 8.  Future directions with hematopoietic growth factors.

Authors:  Saroj Vadhan-Raj
Journal:  J Natl Compr Canc Netw       Date:  2003-01       Impact factor: 11.908

9.  Stimulation of mature unprimed CD8+ T cells by semiprofessional antigen-presenting cells in vivo.

Authors:  H Kosaka; C D Surh; J Sprent
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

10.  Differential regulation of B cell development, activation, and death by the src homology 2 domain-containing 5' inositol phosphatase (SHIP).

Authors:  A Brauweiler; I Tamir; J Dal Porto; R J Benschop; C D Helgason; R K Humphries; J H Freed; J C Cambier
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  55 in total

1.  Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8.

Authors:  Sharmistha Bhattacharyya; Nagaraja S Balakathiresan; Clifton Dalgard; Usha Gutti; David Armistead; Cathy Jozwik; Meera Srivastava; Harvey B Pollard; Roopa Biswas
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

2.  Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP.

Authors:  Michelle M Collazo; Kim H T Paraiso; Mi-Young Park; Amy L Hazen; William G Kerr
Journal:  Eur J Immunol       Date:  2012-07       Impact factor: 5.532

3.  SHIP1 regulates MSC numbers and their osteolineage commitment by limiting induction of the PI3K/Akt/β-catenin/Id2 axis.

Authors:  Sonia Iyer; Dennis R Viernes; John D Chisholm; Bryan S Margulies; William G Kerr
Journal:  Stem Cells Dev       Date:  2014-07-03       Impact factor: 3.272

4.  Human Cytomegalovirus Glycoprotein-Initiated Signaling Mediates the Aberrant Activation of Akt.

Authors:  Jamil Mahmud; Michael J Miller; Aaron M Altman; Gary C Chan
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

Review 5.  The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease.

Authors:  Ana Raquel Ramos; Somadri Ghosh; Christophe Erneux
Journal:  J Lipid Res       Date:  2018-09-07       Impact factor: 5.922

Review 6.  Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL.

Authors:  Michelle Pirruccello; Pietro De Camilli
Journal:  Trends Biochem Sci       Date:  2012-02-28       Impact factor: 13.807

Review 7.  The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves.

Authors:  William G Kerr; John D Chisholm
Journal:  J Immunol       Date:  2019-01-01       Impact factor: 5.422

8.  Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.

Authors:  Gwenny M Fuhler; Robert Brooks; Bonnie Toms; Sonia Iyer; Elizabeth A Gengo; Mi-Young Park; Matthew Gumbleton; Dennis R Viernes; John D Chisholm; William G Kerr
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 9.  Autoimmunity checkpoints as therapeutic targets in B cell malignancies.

Authors:  Markus Müschen
Journal:  Nat Rev Cancer       Date:  2018-01-05       Impact factor: 60.716

10.  Loss of lipid phosphatase SHIP1 promotes macrophage differentiation through suppression of dendritic cell differentiation.

Authors:  Eui Young So; Changqi Sun; Anthony M Reginato; Patrycia M Dubielecka; Toru Ouchi; Olin D Liang
Journal:  Cancer Biol Ther       Date:  2018-10-02       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.